Orexo AB: Clinical Trials

7 trials sponsored by Orexo AB, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 1 terminated. 2 Not applicable, 2 Phase 3, 2 Phase 4, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Not applicable2Completed 2
Phase 32Completed 2
Phase 42Completed 1, Terminated 1
Phase 21Completed 1

Follow Orexo AB: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder
OXD01 digital therapy, Standard of Care - Opioid-use Disorder
Not applicableCompletedOrexo AB4372021-06-302025-06-27
Using Artificial Intelligence To Monitor Medication Adherence in Opioid Replacement Therapy
AiCure monitoring and intervention - Opiate Addiction, Medication Non-adherence
Not applicableCompletedAiCure92016-08-012017-09-12
Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults
BNX sublingual tablets, BNX sublingual film, Buprenorphine - Opioid Dependence, on Agonist Therapy
Phase 3CompletedOrexo AB7592013-08-012017-05-10
Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence
Higher bioavailability BNX sublingual tablets - Opioid Dependence, on Agonist Therapy
Phase 4CompletedOrexo AB6682013-07-012015-10-28
Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence
Buprenorphine/naloxone sublingual tablets, Buprenorphine - Opioid-Related Disorders, Opiate Dependence
Phase 3CompletedOrexo AB3132013-06-012017-05-10
Conversion From Fast Acting Oral Opioids to AbstralĀ®
SL fentanyl - Pain
Phase 4TerminatedOrexo AB82011-02-212017-04-05
Efficacy and Safety Study of BLX-028914 in Subjects With Allergic Rhinitis
BLX-028914, placebo - Allergic Rhinitis
Phase 2CompletedDart NeuroScience, LLC362008-09-012013-03-13

Conditions studied

Opioid-Related Disorders (5)  ·  Behavior, Addictive (1)  ·  Directly Observed Therapy (1)  ·  Medication Adherence (1)  ·  Pain (1)  ·  Patient Compliance (1)  ·  Rhinitis, Allergic (1)

Interventions

Buprenorphine (3)  ·  Buprenorphine, Naloxone Drug Combination (3)  ·  Fentanyl (1)  ·  Methods (1)  ·  Standard of Care (1)

Countries

United States (5)  ·  Sweden (2)

Top investigators

Adam Hanina, MBA, MPhil (1)  ·  Alain Litwin, MD (1)  ·  Anders Pettersson, MD, PhD (1)  ·  David Capano, PharmD (1)  ·  Erik Gunderson (1)  ·  Kent Hoffman (1)  ·  Lennart Greiff, MD, PhD (1)  ·  Lynn Webster (1)

Results publications

PMID 26412801